YUVIWEL - (1.3MG/VIAL, 2.8MG/VIAL, 5.5MG/VIAL; POWDER)

Generic Name	NAVEPEGRITIDE	**Innovator**	ASCENDIS PHARMA BONE
Dosage	1.3MG/VIAL, 2.8MG/VIAL, 5.5MG/VIAL; POWDER	**Branded US Sales**	Less Than $1000 mn
Probable FTF	None	**Known Para IV Filers**	None
Other ANDA developers	None	**Tentative Approvals**	None
Final Approvals	None	**Generic Launches**	None
Indication	YUVIWEL is a C-type natriuretic peptide (CNP) analog indicated to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses.		
Complexities	Yes		

Chronology Of Events
Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary
Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status
Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition
Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events
Please Contact contact@researchdelta.com to get Detailed Information.